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MaOBJECTIVES This study sought to evaluate whether patterns of myocardial change in doxorubicin-induced dilated
cardiomyopathy determined using dual-energy computed tomography (CT) were similar to characterization by extra-
cellular volume fraction (ECV) using cardiac magnetic resonance (CMR) T1-mapping and collagen volume fraction (CVF)
measured using histology.
BACKGROUND Anthracycline chemoagents are effective against a wide range of malignant conditions. However,
cardiotoxicity is a well-known adverse effect of these drugs. Dual-energy CT could be as useful as magnetic resonance
(MR) to evaluate myocardial change in anthracycline-induced cardiotoxicity.
METHODS A dilated cardiomyopathy rabbit model was generated by injecting 11 adult New Zealand rabbits with
1.0 mg/kg of doxorubicin twice weekly for 16 weeks. Contrast-enhanced dual-energy CT and pre-contrast and post-
contrast T1-mapping CMR using a prototype modiﬁed Look-Locker inversion recovery on a clinical 3-T scanner were
performed on 15 rabbits, including 4 control animals, to calculate ECV at baseline, and at 6, 12, and 16 weeks after
doxorubicin administration.
RESULTS The mean ECV values (%) on CT and CMR at 6, 12, and 16 weeks after modeling were signiﬁcantly higher
than those measured at baseline (CT ECV: 35.3%, 41.9%, 42.1% vs. 28.5%; MR ECV: 32.6%, 35.8%, 41.3% vs. 28.8%,
respectively; all p < 0.001). CT ECV and MR ECV values were well correlated (r ¼ 0.888; p < 0.001). Both were well
correlated with CVF on histology (CT ECV vs. CVF, r ¼ 0.925, p < 0.001 and MR ECV vs. CVF, r ¼ 0.961, p < 0.001,
respectively).
CONCLUSIONS Dual-energy CT ECV correlated well with CMR and histology. Dual-energy CT is useful for character-
izing doxorubicin-induced cardiomyopathy by measuring ECV fraction; however, further technical improvements are
desirable to lower motion artifact and improve image quality of the iodine map. (J Am Coll Cardiol Img 2016;9:836–45)
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
CT = computed tomography
CVF = collagen volume
fraction
DCM = dilated cardiomyopathy
ECV = extracellular volume
fraction
Hct = hematocrit
HU = Hounsﬁeld unit
ICC = intraclass correlation
coefﬁcient
LGE = late gadolinium
enhancement
LV = left ventricle
LVEF = left ventricular
ejection fraction
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837A nthracycline chemoagents are effectiveagainst a wide range of malignant conditions(1). However, cardiotoxicity is a well-known
adverse effect of these drugs that causes diffuse and
irreversible myocardial ﬁbrosis (2). This damage to
the myocardial structure is known to be associated
with adverse cardiac events (3,4).
Myocardial T1-mapping cardiac magnetic reso-
nance (CMR) is an emerging technique that could
improve detection of diffuse interstitial myocardial
ﬁbrosis caused by chemotherapy-induced cardiotox-
icity by measuring the extracellular volume (ECV)
fraction (5,6). A few recent studies used computed
tomography (CT) to detect diffuse myocardial ﬁbrosis
(7,8). These studies were based on the theory that
iodine contrast agents used in CT and gadolinium
agents used in CMR, despite their different molecular
structures (9), have similar kinetics, molecular
weights, and ECV of distribution.FIGURE 1 Experiment Flow Chart
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The process of the experiment of the CT, MR scanning, and
histological examination in rabbit models. CT ¼ computed
tomography; MR ¼ magnetic resonance.
SEE PAGE 846
MR = magnetic resonance
= regions of interestDual-energy CT is an advanced imaging technique
that can provide additional information regarding
material composition using 2 different x-ray spectra
data sets (10). There are no prior reports on the
quantiﬁcation of the ECV using dual-energy CT in
diffuse myocardial ﬁbrosis patients.
We hypothesized that dual-energy CT would be
valuable for extracting the iodine component of
the myocardium, and for assessing CT ECV in
a doxorubicin-induced cardiomyopathy model.
Accordingly, this study aimed to validate ECV using
dual-energy CT, to compare CT ECV with parallel
contrast-enhanced CMR measurements, and to assess
histological collagen volume fraction (CVF) in a rabbit
model of doxorubicin-induced dilated cardiomyo-
pathy (DCM).
METHODS
ANIMAL MODELING AND EXPERIMENT FLOW
CHART. All experiments were approved by the ani-
mal care and use committee at our institution and
experiments were performed according to the Na-
tional Institutes of Health guidelines. Twenty adult
male New Zealand white rabbits weighing 3 to 4 kg
were included. Among them, 4 rabbits served as
control subjects for histological evaluations. The
remaining 16 rabbits received 1.0 mg/kg injections of
doxorubicin (doxorubicin hydrochloride, Cayman
Chemical, Ann Arbor, Michigan) twice weekly until
they were sacriﬁced for histological evaluations (11).
For drug administration, the auricular vein was
accessed by introduction of a 21-gauge needle.Doxorubicin (1.0 mg/kg) was diluted in 20 ml
of 0.9% sterile saline and slowly injected over
3 min using the bolus injection method.
Among the 16 rabbits, 5 died during the
modeling period from severe anemia (n ¼ 3)
or infection (pneumonia, n ¼ 2). At the end of
the 6-week modeling period, the remaining
subjects (n ¼ 11) underwent post-modeling CT
and CMR scans. Subsequently, 3 rabbits were
sacriﬁced for histological evaluation. The
remaining rabbits (n ¼ 8) continued DCM
modeling, and underwent scans at the end of
the 12-week modeling period. An additional 3
rabbits were sacriﬁced at 12 weeks. The
remaining rabbits continued DCM modeling
(n ¼ 5), and underwent scans at the end of the
16-week modeling period. Afterward the 5
remaining rabbits were sacriﬁced for histo-
logical evaluation (Figure 1).
CT AND MR IMAGING EXAMINATIONS. The
rabbits underwent CT and magnetic reso-
nance (MR) examination before drug adminis-
tration (control subject), and at the end of speciﬁc
ROI
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838post-modeling intervals (6, 12, or 16 weeks after DCM
modeling). Before CT examination, the rabbits were
anesthetized with an intramuscular injection of
tiletamine, 30 mg/kg (Zoletil, Vibac Laboratories,
Carros, France) and xylazine, 5 mg/kg (Rompun,
Bayer, Seoul, Korea), and the anterior chest wall of
each rabbit was shaved for electrocardiogram elec-
trodes placement. Both auricular veins of each rabbit
were prepared for venous access for contrast injection
and administration of medetomidine hydrochloride,
0.3 mg/kg (Tomidine, Provet Veterinary Products
Ltd., Istanbul, Turkey). Venous sampling was per-
formed to obtain hematocrit (Hct) values for all rab-
bits immediately before the CT examinations. The
animals were intubated and mechanically ventilated
(Mekant, MEKICS, Seoul, Korea) using a mixture of
oxygen and isoﬂurane. The ventilator was not CMR-
compatible and was thus placed outside the CMR
room with the long respiratory tubes entering the
room.
CT PROTOCOL. Dual-energy CT was performed using
a dual-source CT (Somatom Deﬁnition Flash, Siemens
Healthcare, Forchheim, Germany) with retrospective
electrocardiogram-gated scanning. Scan parameters
were as follows: 185 effective mA at 100 kV, and 157
effective mA at 140 kV with a tin ﬁlter, 64  0.6 mm
collimation, 0.32 pitch factor, and 0.28-s rotation
time. After a bolus injection of 2 ml/kg contrast
medium (Pamiray 370, Dongkook Pharmaceutical,
Seoul, Korea), 8 to 10 ml of normal saline was infused
at a rate of 1.5 to 1.7 ml/s through the auricular vein of
each rabbit. The initial post-contrast scan started at
3 min, and additional scans were obtained at 5, 7, 9,
11, 13, and 20 min after contrast injection. Each rabbit
was administered a bolus injection of 0.3 mg/kg of
medetomidine to reduce heart rate 30 s before
each scan.
Dual-energy CT data post-processing. All CT data were
processed on a dedicated workstation equipped with
dual-energy post-processing software (syngo MMWP
VE 36A, Siemens Healthcare). The Online Appendix
provides detailed steps.
CMR PROTOCOL. CMR was performed immediately
after dual-energy CT and completed within 2 h. A
3.0-T MR scanner (Magnetom Trio Tim, Siemens
Healthcare, Erlangen, Germany) with a 6-channel
anterior body matrix coil, and the posterior part of a
12-channel head matrix coil was used. Localization of
the heart was achieved using a steady-state free
precession sequence under electrocardiogram gating.
Cine, late gadolinium enhancement (LGE), and pre-
contrast and post-contrast T1-mapping images
were acquired. For cardiac functional analysis, cineimages were acquired using a TrueFISP sequence in
the short-axis plane orientation. T1-mapping was
performed using a prototype modiﬁed Look-Locker
inversion recovery sequence during the end-
expiratory period in short axis view at mid-ventricle.
Pre-contrast T1-mapping images were acquired
before the injection of contrast. Post-contrast
T1-mapping images were acquired 1, 3, 5, 7, 9, 11, 13,
and 20 min after the injection of a 0.2 mmol/kg intra-
venous dose of gadolinium contrast agent (Omniscan,
GE Healthcare, Princeton, New Jersey). LGE imaging
was obtained 15 min after the injection of the contrast
agent using a magnitude- and phase-sensitive inver-
sion recovery-prepared steady-state free precession
sequence (see the Online Appendix for the detail
protocol).
IMAGE ANALYSIS. Two radiologists (Y.J.H., C.H.P.),
both of whom had 9 years of experience in cardio-
vascular image interpretation, analyzed all images.
CT image analysis. CT ECV (%) and post-contrast
Hounsﬁeld unit (HU) were measured on a PACS sys-
tem. The same image, with MR short axis mid–left
ventricle (LV) where the papillary muscles were
visible, was chosen from the 13-min iodine map and
post-contrast image. The regions of interest (ROI)
were drawn at the septal segment, and a round ROI
($10 mm2) that avoided the papillary muscle was
drawn in the LV cavity (Figure 2A). The mean atten-
uation at the ROI was recorded in HU. Myocardial CT
ECV (ECVm) was calculated using the following for-
mula (Equation 1):
ECVm ¼ ðHUm=HUbÞ  ð1HctÞ
where ECVm is myocardial ECV in dual-energy CT,
HUm is HU corresponding to the myocardium ROI on
the iodine map, and HUb is HU corresponding to the
blood pool on the iodine map.
CT ECV map software development. CT ECV maps were
quantiﬁed by a custom-developed software package
written in MATLAB version 2014a (The MathWorks,
Inc., Natick, Massachusetts). The Online Appendix
provides detailed steps.
Evaluation of the image quality of the CT iodine map and
T1 map images. The image quality of the iodine maps
generated 3, 5, 7, 9, 11, 13 and 20 min after contrast
injection was determined using a subjective 4-point
scale based on image degradation and demarcation
between the LV myocardium and cavity. According to
the scale, 4 ¼ excellent, no image degradation, clear
demarcation between LV myocardium and cavity;
3 ¼ good, minor degree of image degradation without
affecting diagnostic accuracy; 2 ¼ adequate, moderate
degree of image degradation that slightly affected
FIGURE 2 Measurement on CT and Cardiac Magnetic Resonance
(A) The CT regions of interest were drawn at the septal segment and cavity of left ventricle on the iodine map. On the pre-contrast T1-map
(B) and post-contrast T1-map CMR images (C), regions of interest were drawn at the same areas as the CT. Abbreviations as in Figure 1.
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839diagnostic accuracy but images were still used for
diagnosis; and 1 ¼ poor, severe image degradation
that greatly affected diagnostic accuracy and resulted
in nondiagnostic poor images. Pre-T1 and post-T1
map CMR images were scored using the Peter Kell-
man scale (12). Online Figure 1 shows representative
images of iodine maps and the image qualities of
CMR map images.
Functional CMR image analysis. All CMR cine images
were transferred to commercially available software
(Argus, Siemens Medical Solutions, Erlangen,
Germany). The LV function was assessed on the short-
axis cine CMR images using the Simpson method.
CMR image analysis for the measurement of ECV fraction
(%). All CMR images were transferred to a PACS sys-
tem for image analysis. The ROIs at the same septal
segment measured on CT were drawn on the pre-
contrast and post-contrast T1-mapping image at the
mid-LV where papillary muscles were visible. For a
measurement of the T1 blood value, a round ROI
($5 mm2) that avoided papillary muscles was drawn
in the LV cavity (Figures 2B and 2C). The ECV fraction
was calculated from Equation 2 as follows:
ECV¼ 1T1post-contrastmyocardium

1T1pre-contrastmyocardium

1

T1post-contrastblood

1T1pre-contrastblood
ð1HctÞ
HISTOLOGICAL ANALYSIS. For histology, samples
from the LV were obtained immediately after eutha-
nasia accomplished by KCl injection, and ﬁxed in 10%
phosphate buffered paraformaldehyde. After 1 week
of ﬁxation, the tissue was dissected at the short axis
plane at mid-LV level where the papillary muscleswere visible, using a rabbit heart slicer (Zivic In-
struments, Pittsburgh, Pennsylvania). The fragments
were dehydrated in solutions of decreasing alcohol
concentration, cleared in xylene, and embedded in
parafﬁn. Ten-micrometer sections were obtained and
prepared for analysis by picrosirius red staining.
CVF (%) analysis. An independent researcher blinded
to the CT and CMR results performed the histological
analyses. Each histological section was obtained at
the septal segment at mid-LV. Histopathologic image
analyses were performed using ImageJ (National
Institutes of Health, Bethesda, Maryland). The Online
Appendix provides detailed steps.
STATISTICAL ANALYSES. All continuous data were
expressed as the mean  SD, and categorical variables
were presented as numbers or percentages. CT ECV
and MR ECV at 13 min were compared with histologic
CVF using Spearman correlation. The correlation
between myocardial CT ECV and MR ECV at 13 min
was also assessed using a mixed model by the
Hamlett method to account for repeated measure-
ments over several weeks (13). The change in CT ECV
values according to the scan time and the change in
CT ECV, post-contrast HU, MR ECV, and pre-T1 values
according to the modeling time (between control and
6, 12, and 16 weeks after modeling) were evaluated by
a linear mixed model with restricted maximum like-
lihood estimation using the MIXED procedure in SAS
version 9.2 (SAS Institute, Cary, North Carolina). The
linear mixed model included ﬁxed effects for time,
and random intercept for each animal. Time was
considered as a categorical variable in the model and
the covariance was assumed to be equal among all
time points.
TABLE 1 Physiologic
Hematocrit, %
Left ventricular ejectio
fraction, %
End-diastolic volume, m
End-systolic volume, m
Stroke volume, ml
Cardiac output, ml/min
Left ventricle mass, g/
Values are median (range)
p < 0.05. ‡Control vs. 16-
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840Agreement between the measures of CT, MR ECV,
pre-T1, and post-contrast HU between the 2 observers
was assessed using the intraclass correlation coefﬁ-
cient (ICC) and Bland-Altman plot (14). The receiver
operating characteristic curve was reconstructed
using the Obuchowski method to compare the diag-
nostic performance of CT ECV and MR ECV with that
of the left ventricular ejection fraction (LVEF) for the
diagnosis of modeling subjects (15). All statistical
analyses were performed using Statistical Package for
the Social Science software version 20 (SPSS Inc.,
Chicago, Illinois) and SAS version 9.2 (SAS Institute
Inc.), and p < 0.05 was considered statistically
signiﬁcant.
RESULTS
PHYSIOLOGICAL AND FUNCTIONAL DATA. The Hct
levels in DCM rabbits were lower than those in control
subjects. The Hct level of control subjects was 42.3%
(36.9% to 54.8%), whereas that of 6-week model was
33.2% (18.7% to 46.2%) (Table 1). In the DCM rabbit
model, ventricular chamber enlargement and LV wall
thinning were noted. The mean LVEF for post-
modeling subjects was signiﬁcantly lower than the
control subjects (Table 1).
DUAL-ENERGY CT VERSUS CMR. Validation of CT and
CMR protocol. The CT ECV results revealed no signiﬁ-
cant changes from 3 min to 20 min in all subjects
(control subject, p ¼ 0.208; 6-week modeling sub-
jects, p ¼ 0.827; 12-week modeling subjects, p ¼
0.877; 16-week modeling subjects, p ¼ 0.916). MR ECV
results also revealed no signiﬁcant changes from
3 min to 20 min in all subjects (control subject, p ¼
0.782; 6-week modeling subjects, p ¼ 0.894; 12-week
modeling subjects, p ¼ 0.691; 16-week modeling
subjects, p ¼ 0.831) (Figures 3A to 3D).
Image quality of CT iodine maps. In total, 254 septal
segments on the iodine map were analyzed across allal and Functional Data For All Subjects
Control Subjects
(n ¼ 15)
6-Week Model
(n ¼ 11)
12-Week Model
(n ¼ 8)
16-Week Model
(n ¼ 5)
42.3 (36.9–54.8) 33.2 (18.7–46.2) 33.0 (24.9–42.1) 37.3 (25.4–43.0)
n 54.7  3.2 44.3  4.3* 36.2  9.3† 32.0  11.0‡
l 2.3  0.8 2.0  0.7 2.3  0.6 3.1  0.9
l 1.0  0.4 1.2  0.4 1.6  0.8 2.0  0.6
1.2  0.4 0.9  0.3 0.7  0.2 1.1  0.3
273.7  85.7 168.2  57.0 120.9  39.5 148.4  34.1
kg 0.8  0.1 0.9  0.2 1.1  0.2 1.1  0.2
or mean  SD. *Control vs. 6-week model, p < 0.05. †Control vs. 12-week model,
week model, p < 0.05.subjects. Of these, 238 segments (93.7%) were of
diagnostic quality (score ¼ 2 to 4). Speciﬁcally, 61
segments (24.0%) were excellent (score ¼ 4), 106
segments (41.7%) were good (score ¼ 3), 71 segments
(28.0%) were adequate (score ¼ 2), and 16 segments
(6.3%) were nondiagnostic (score ¼ 1). Nondiagnostic
segments were excluded from the image analysis.
Dual-energy CT and MR: ECV comparison. The mean CT
ECV of the control subjects (n ¼ 15) was 28.5% (25.9%
to 31.3%) and that of 6-, 12-, and 16-week models was
35.3% (30.2% to 40.1%), 41.9% (35.6% to 44.1%), and
42.1% (39.2% to 46.4%), respectively. The mean MR
ECV of the control subjects (n ¼ 15) was 28.8%
(26.1% to 30.8%) and that of 6-, 12-, and 16-week
models was 32.6% (29.9% to 34.3%), 35.8% (31.0% to
39.8%), and 41.3% (38.4% to 47.3%), respectively
(Table 2). Figure 4 shows the serial change in color
maps of the LV according to the modeling time and
ECV values. The interobserver agreement for CT and
MR ECV measurements was good (ICC 0.902 [95%
conﬁdence interval (CI): 0.920 to 0.947] for CT ECV;
ICC 0.953 (95% CI: 0.911 to 0.975) for MR ECV). A good
correlation existed between CT ECV and MR ECV
across all subjects (n ¼ 26; r ¼ 0.888; p < 0.001), and
across post-modeling subjects (n ¼ 11; r ¼ 0.840; p <
0.001). Bland-Altman plots between CT and MR ECV
showed small bias (1.406%) with 95% limits of
agreement from –3.457% to 6.269% between CT and
MR ECV (Figure 5).
Dual-energy CT and MR: other values and diagnostic
performance. The mean post-contrast HU of control
subjects was 58.0 HU (range 51 to 70 HU) and that
of 6-, 12-, and 16-week models was 60.2 HU (range
50 to 77 HU), 68.4 (range 61.2 to 76.9 HU), and 69.4
(range 62.6 to 73.1 HU), respectively. The mean pre-
T1 value of control subjects was 1,068.1 ms (range
1,030.0 to 1,103.85 ms) and that of 6-, 12-, and
16-week models was 1,110.3 ms (range 1,075.2 to
1,175.0 ms), 1,118.2 ms (range 1,059.2 to 1,160.8 ms),
and 1,121.3 ms (range 1,104.5 to 1,121.8 ms),
respectively. The ICC for pre-T1 value was 0.628
(95% CI: 0.393 to 0.786) and that for post-contrast
HU was 0.727 (95% CI: 0.536 to 0.847).
The mean post-contrast HU of 12- and 16-week
models was signiﬁcantly higher than that of the
control subjects, and the mean pre-T1 value of all
post-modeling subjects was signiﬁcantly higher than
that of the control subject (Table 2). In LGE imaging,
there was no focal LGE in the post-models. When
we used CT ECV, MR ECV, and LVEF for diagnosis
of post-modeling subjects, the areas under the
receiver operating characteristic curve of CT ECV,
MR ECV, and LVEF were 0.997 (95% CI: 0.990
to 1.000), 1.000 (95% CI: 1.000 to 1.000), and
FIGURE 3 Change in CT, MR ECV Over Time After Contrast Injection
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Mean CT and MR ECV did not change signiﬁcantly at 3 to 20 min in control and models. (A) Change in CT, and MR ECV over time after
contrast injection in control subjects (p ¼ 0.208 for CT ECV; p ¼ 0.782 for MR ECV), (B) 6-week modeling subjects (p ¼ 0.827 for CT ECV;
p ¼ 0.894 for MR ECV), (C) 12-week modeling subjects (p ¼ 0.877 for CT ECV; p ¼ 0.691 for MR ECV), and (D) 16-week modeling subjects
(p ¼ 0.916 for CT ECV; p ¼ 0.831 for MR ECV). ECV ¼ extracellular volume fraction; other abbreviations as in Figure 1.
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8410.967 (95% CI: 0.899 to 1.000), respectively. There
was no signiﬁcant difference between areas under the
receiver operating characteristic curve.
HISTOLOGY. Collagen ﬁbers located in the extracel-
lular space were stained red following picrosirius red
staining. The CVF showed a steady increase according
to the modeling time (Figure 6).
The mean CVF of the control subjects (n ¼ 4) was
3.3% (2.9% to 4.1%). The mean CVF of 6 (n ¼ 3), 12
(n ¼ 3), and 16 (n ¼ 5) week models was 12.7% (11.4%
to 14.1%), 20.1% (16.7% to 25.2%), and 29.3% (19.3% to
38.3%), respectively. Figure 7 demonstrates the his-
tological examples of the control and modeling
subjects.
CT ECV obtained using dual-energy CT correlated
with histological CVF ﬁndings (n ¼ 15; r ¼ 0.925;
p < 0.001). Similarly, MR ECV correlated with histo-
logical CVF (n ¼ 15; r ¼ 0.961; p < 0.001).DISCUSSION
This study aimed to validate ECV fraction using
dual-energy CT, and to compare the results with
contrast-enhanced CMR values and histological ﬁnd-
ings for evaluation of diffuse myocardial ﬁbrosis in a
doxorubicin-induced DCM rabbit model. CT ECV map
software that depicted ECV on a color-coded map
with a percentage scale was also developed. Changes
in ECV can be determined at a glance using CT
ECV maps.
Recently, myocardial ﬁbrosis imaging based on
T1-mapping and measurement of ECV has been
regarded as a promising tool for detecting and quan-
tifying diffuse myocardial ﬁbrosis (5,6). Nacif et al. (8)
reported on the usefulness of myocardial ECV mea-
surements using bolus injection contrast-enhanced
CT and found that the cardiac CT and MR ECVs were
TABLE 2 CT and MR ECV and Histologic CVF in All Subjects
Control Subjects
(n ¼ 15)
6-Week Model
(n ¼ 11)
12-Week Model
(n ¼ 8)
16-Week Model
(n ¼ 5)
CT ECV, % 28.5 (25.9–31.3) 35.3* (30.2–40.1) 41.9† (35.6–44.1) 42.1‡ (39.2–46.4)
MR ECV, % 28.8 (26.1–30.8) 32.6* (29.9–34.3) 35.8† (31.0–39.8) 41.3‡ (38.4–47.3)
CVF, % 3.3§ (2.9–4.1) 12.7k (11.4–14.1) 20.1k (16.7–25.2) 29.3¶ (19.3–38.3)
Pre-T1, ms 1,068.1 (1,030.0–1,103.85) 1,110.3* (1,075.2–1,175.0) 1,118.2† (1,059.2–1,160.8) 1,121.3‡ (1,104.5–1,121.8)
Post-contrast HU 58.0 (51–70) 60.2 (50–77) 68.4† (61.2–76.9) 69.4‡ (62.6–73.1)
Values are mean (range). *Control vs. 6-week model, p < 0.05. †Control vs. 12-week model, p < 0.05. ‡Control vs. 16-week model, p < 0.05. §n ¼ 4. kn ¼ 3. ¶n ¼ 5.
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography; CVF ¼ collagen volume fraction; ECV ¼ extracellular volume fraction; HU ¼ Hounsﬁeld unit.
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842higher in patients with heart failure than in healthy
control subjects. Additionally, the results indicated a
good correlation between cardiac CT ECV and MR ECV
values (8).
In a separate study, Bandula et al. (7) developed
and validated an equilibrium contrast-enhanced CT
protocol involving continuous infusion after bolusFIGURE 4 Examples of CT ECV Maps in Control and Models
(A) Control subject (Hct ¼ 44.4%), ECV ¼ 27.0%; dark blue normal myo
ECV ¼ 36.4%; dark blue septal wall changed to bright blue. (C) Twelve
inferoseptal/inferolateral wall changed to bright blue myocardium. (D)
myocardium suggests myocardial ﬁbrosis. Hct ¼ hematocrit; other abbrinjection. Equilibrium CT ECV was strongly correlated
to equilibrium MR ECV, and exhibited a signiﬁcant
correlation with histological ﬁbrosis. Thus, prior
studies have demonstrated the possibility of quanti-
fying myocardial ﬁbrosis using cardiac CT. In the
current study, we sought to establish the validity of
dual-energy CT by CT ECV measurement and comparecardium shown on the ECV map. (B) Six-week model (Hct ¼ 37.4%),
-week model (Hct ¼ 30.0%), ECV ¼ 44.0%; dark blue area of
Sixteen-week model (Hct ¼ 25.0%), ECV ¼ 46.0%; bright blue
eviations as in Figures 1 and 3.
FIGURE 5 Bland-Altman Plots for the CT and MR ECV on Per Subject Analysis
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Small bias (1.406%) was noted with 95% limits of agreement from -3.457% to 6.269%
between CT and MR ECV. Abbreviations as in Figures 1 and 3.
FIGURE 6 Mean Histological CVF (%) in the Control and Models
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The graph showed a steady increase of CVF according to the modeling time.
CVF ¼ collagen volume fraction.
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843it with MR ECV for evaluating diffuse ﬁbrosis in
doxorubicin-induced cardiotoxicity in a rabbit model.
CT offers several advantages over MR, including
coverage of the whole myocardium in a short scan-
ning time, and widespread availability (7). Addition-
ally, CT can be substituted for CMR in case of
contraindications (e.g., CMR-unsafe devices and
claustrophobia).
However, previous studies used conventional CT
with both pre-contrast and post-contrast equilibrium
CT (7,8). For the analyses, ROIs in the myocardial
septum were selected on the post-contrast image,
whereas the corresponding areas on the pre-contrast
image were selected by visual estimation. This
method led to mis-registration errors because of
changes in the pre-contrast and post-contrast CT
acquisition location. More importantly, the radiation
exposure was doubled.
Consequently, the method used in the current
study was changed to dual-energy CT, which uses
data acquired at the time of the scan to produce both
pre-contrast and post-contrast images. Moreover,
dual-energy CT can simultaneously provide data from
CT images obtained at 2 different x-ray spectra (10).
Difference in material composition was shown
because the different photon absorption rates were
affected by the data in the 2 spectra (10,16). In this
study, the major advantages of dual-energy CT were
the lack of mis-registration errors that occurred
from pre-contrast and post-contrast scanning with
different scanning times and at different positions.
An iodine map was simultaneously reconstructed
from contrast image data acquired at 100 and 140
kVp. The one scan was sufﬁcient to visualize delayed
contrast-enhancement, thus eliminating the require-
ment for the 2-step process of obtaining pre-contrast
and post-contrast scans.
This study is the ﬁrst to assess CT ECV using dual-
energy CT. To determine the proper scanning
parameters and to ﬁnd the stabilization point for CT
ECV, scans were performed at 3, 5, 7, 9, 11, 13, and 20
min after contrast injection. CMR scans were also
performed at those time points for comparison. CT
ECV values did not signiﬁcantly change throughout
the scanning in all subjects. The MR ECV in this study
was also stabilized at 3 min after contrast injection.
The previous studies showed similar result that
human ECV stabilized at approximately 5 min after
contrast injection (17–19).
Equation 2 was used for calculating ECV values. In
the dual-energy CT measurement, the corresponding
HU of the ROI on the iodine map represented the
degree of enhancement of the measured area. The HU
of the ROI on the iodine map was sufﬁcient tomeasure HU in the myocardium and blood cavity.
A software program that measured CT ECV and
generated a color-coded iodine map illustrating the
distribution of iodine contrast in the myocardium
was developed. Furthermore, the software enabled
quantiﬁcation of the myocardial enhancement
using the HU reported on the iodine map. Although
FIGURE 7 The Histological Example of the Control and 6-, 12-, and 16-Week Models
Collagen volume fraction values of (A) 2.1%, (B) 11.8%, (C) 24.9%, and (D) 44.7%, respectively (picrosirius red, original magniﬁcation 200).
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844CMR has been the standard for imaging ﬁbrosis, the
potential beneﬁts of CT warrant recognition because
CT enables rapid, widely available, and economical
imaging.
In addition, this study demonstrated proof of
concept using an animal model. Further studies are
required for assessment in humans. The estimated
radiation dose for humans would be 3 to 4 mSv (20).
When considering hazards of CT, clinical utility of CT
ECV in high-risk cancer patients is quite limited. An
additional method (e.g., iterative reconstruction)
might lower the radiation burden and make this
technique feasible for clinical application in humans.
STUDY LIMITATIONS. The limitations of the current
study included the small sample size and motion ar-
tifacts from the fast heart rate or arrhythmia of the
rabbits. Although a drug was used to reduce heart rate,
the mean heart rates of the pre-modeling and post-
modeling animals were 114.3  13.0 beats/min and
98.2  8.2 beats/min, respectively. Such a high heart
rate would not be encountered in humans. How-
ever, arrhythmia would be encountered frequently.
Retrospective gating mode would be helpful foracquiring accessible image quality. However, consid-
erable amount of radiation exposure will still be a
problem. CT ECV was correlated with histological
assessments of CVF. Because there is no direct method
for measuring histological ECV, the relationship
between CT ECV and histological ECV could not be
evaluated. Nonetheless, the correlation between CT
ECV and histological CVF was statistically signiﬁcant.
Our study showed that ECV changes can be detected by
using both MR and CT, and that these are comparable
with the signiﬁcant changes in LVEF determined using
CMR. CMR ejection fraction can be adequate for
detection of cardiotoxicity based on the result of the
study in which the diagnostic values of CT, MR ECV,
and ejection fraction in detecting cardiotoxicity were
not signiﬁcantly different. Further study is required
to determine the most sensitive method for early
detection of cardiotoxicity.
CONCLUSIONS
This study demonstrated that dual-energy CT for
computing CT ECV is a feasible, noninvasive method
for quantitatively measuring diffuse myocardial
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This pilot study
established the necessary steps for conducting a broader exam-
ination of dual-energy CT, CMR, and the histological assessment
of doxorubicin-induced cardiotoxicity. Although CMR has been
the standard for imaging ﬁbrosis, the potential beneﬁts of using
dual-energy CT warrant recognition.
TRANSLATIONAL OUTLOOK: This study demonstrated
proof of concept using an animal model. Further studies are
required for assessment in humans. When transferring this
method for humans, optimal scan parameters, such as the
amount of contrast dose, and delayed imaging time should
be investigated.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 9 , N O . 7 , 2 0 1 6 Hong et al.
J U L Y 2 0 1 6 : 8 3 6 – 4 5 Myocardial Imaging With Dual-Energy CT
845ﬁbrosis. However, further technical improvements
are desirable to lower motion artifact and radiation
exposure.
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